These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 3806806

  • 1. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL.
    J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806
    [Abstract] [Full Text] [Related]

  • 2. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO, Dresner SM, Ratliff TL, Catalona WJ.
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM.
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [Abstract] [Full Text] [Related]

  • 5. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ.
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [Abstract] [Full Text] [Related]

  • 6. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL.
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [Abstract] [Full Text] [Related]

  • 7. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF.
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [Abstract] [Full Text] [Related]

  • 8. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB, Huang MY, Lindner A, Smith RB, Kaufman JJ.
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [Abstract] [Full Text] [Related]

  • 9. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Sarosdy MF, Lamm DL.
    J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Retrospective study of efficacy of intravesical BCG alone in treatment of superficial bladder cancer.
    Mydlo JH, Usher SM, Camacho F, Freed S.
    Urology; 1986 Sep; 28(3):173-5. PubMed ID: 3750596
    [Abstract] [Full Text] [Related]

  • 12. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW, Pinsky CM, Whitmore WF, Sogani PC, Oettgen HF, Melamed MR.
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [Abstract] [Full Text] [Related]

  • 13. Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerin.
    Bretton PR, Herr HW, Kimmel M, Fair WR, Whitmore WF, Melamed MR.
    J Urol; 1989 Jun; 141(6):1332-6. PubMed ID: 2724430
    [Abstract] [Full Text] [Related]

  • 14. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
    Brosman SA.
    J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
    [Abstract] [Full Text] [Related]

  • 15. Bladder cancer immunotherapy.
    Lamm DL, Thor DE, Stogdill VD, Radwin HM.
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [Abstract] [Full Text] [Related]

  • 16. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
    Catalona WJ, Ratliff TL.
    Surg Annu; 1990 Nov; 22():363-78. PubMed ID: 2408170
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer.
    Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL.
    J Urol; 1988 May; 139(5):941-4. PubMed ID: 3361668
    [Abstract] [Full Text] [Related]

  • 18. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moskovitz B, van der Heijden AG, Witjes JA.
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
    Steg A, Belas M, Leleu C, Boccon-Gibod L.
    Prog Clin Biol Res; 1989 Jun; 303():375-81. PubMed ID: 2780654
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.